Skip to content
Open access

Cost implications of broad genomic profiling among Medicare patients with metastatic lung cancer.

Oct 2026 · JCO Oncology Practice · 0 citations

Abstract

37 Background: Broad genomic profiling (BGP) is increasingly used in metastatic non-small cell lung cancer (mNSCLC), but its association with downstream treatment-related Medicare spending compared to focused gene testing (FGT) remains unclear. Methods: We conducted a retrospective cohort study using SEER-Medicare data for beneficiaries aged ≥66 years diagnosed with de novo mNSCLC from 2017-2021. Patients receiving BGP vs FGT within 2 months before through 6 months after diagnosis were identified using claims-based algorithms. We used 1:1 propensity score matching, based on sociodemographic, geographic, clinical, tumor histology, diagnosis-year, and pre-diagnosis healthcare utilization to compare BGP and FGT testing groups. We calculated monthly Medicare per-member-per-month (PMPM) payer spending during the 12 months after diagnosis among all matched patients, regardless of survival through 12 months. All costs were adjusted to 2022 US dollars using the Consumer Price Index and cost ratio was estimated using gamma log-link models in the matched cohort. Results: Among 8,983 patients, 5,596 (62.3%) received BGP and 3,387 (37.7%) received FGT; 5,030 patients were included in the matched cohort. Mean 12-month payer spending in the matched sample was $17,342 for BGP versus $16,575 for FGT with a cost ratio for BGP versus FGT of 1.05 (95% CI, 1.003-1.091). BGP testing accounted for $444 PMPM (2.6% of overall costs), while FGT testing accounted for $87 (0.5%). Systemic therapy PMPM costs were higher for BGP versus FGT ($5,831 versus $5,113). BGP patients had higher use of all three types of systemic therapy: targeted therapy, immunotherapy and chemotherapy versus FGT (p<.001). Similarly, spending on targeted therapy ($1,171 versus $898, p<.001) and immunotherapy ($4,181 versus $3,794, p<.001) was higher for BGP versus FGT patients. Conclusions: Among Medicare beneficiaries with mNSCLC, BGP was associated with moderately higher costs than FGT, which was largely attributable to higher spending on and utilization of immunotherapy in the BGP group. These findings suggest that the economic impact of BGP in mNSCLC is driven less by the direct cost of genomic testing and more by the downstream treatment selection associated with its use. Metrics Focused gene testing (n=2,515) Broad genomic profiling (n=2,515) Mean Medicare PMPM Payer Spending $16,575 $17,342 Genomic Testing Payer Spending $87 $444 Systemic Therapy Spending (% Received) $5,113 (72.0%) $5,831 (78.3%) Targeted Therapy $898 (10.5%) $1,171 (13.8%) Immunotherapy $3,794 (54.5%) $4,181 (59.8%) Chemotherapy $422 (63.1%) $480 (68.3%)

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.